United States Patent Granted to Biotranex for MDR3cyte® Assay

Biotranex LLC, an innovative biotech service company at the forefront of developing and offering drug transporter assays, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company United States patent number 10,280,401, which covers its novel multidrug resistance protein 3 (MDR3 or ABCB4) inhibition assay that is marketed as MDR3cyte®.

MONMOUTH JUNCTION, N.J. (PRWEB) May 15, 2019 -- Biotranex LLC, an innovative biotech service company at the forefront of developing and offering drug transporter assays, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company United States patent number 10,280,401, which covers its novel multidrug resistance protein 3 (MDR3 or ABCB4) inhibition assay that is marketed as MDR3cyte®. The patent is entitled “Method for Measuring Phosphatidylcholine Transport and/or Formation Activity.”

The MDR3 hepatic transport protein is responsible for biliary secretion of phosphatidylcholine (PC). Dysfunction of human MDR3 is associated with a wide spectrum of liver diseases, such as progressive familial intrahepatic cholestasis type 3 (PFIC3), intrahepatic cholestasis of pregnancy (ICP), low-phospholipid-associated cholelithiasis, primary biliary cirrhosis, cholangiocarcinoma, and drug-induced liver injury (DILI).

This physiologically relevant hepatocyte-based system, MDR3cyte®, allows for measurement of MDR3 inhibition by chemical entities, drugs and drug candidates in human as well as animal hepatocyte preparations. The MDR3cyte® assay is suitable for use in an early screening strategy or in more detailed mechanistic investigations.

"The role that inhibition of liver transporters, including MDR3, plays in drug-induced liver injury is only recently being appreciated in the pharmaceutical and biotech industries," states Dr. Kan He. The MDR3cyte® assay employs a platform using human or animal hepatocytes in a multi-well plate format with liquid chromatography-mass spectrometry quantification. The assay is reproducible, sensitive, flexible, robust, and possesses a wide dynamic concentration range.

Dr. He further states, "We are pleased to introduce this validated MDR3cyte® assay, which combined with our BSEPcyte® and BilirubinCyte™ assays, offers a more expansive profile of a test agent’s ability to cause DILI."


Contacts:
Kan He, Ph.D. - President
Khe(at)biotranex(dot)com
(732) 230-3062

Thomas F. Woolf, Ph.D. - Senior Vice President
Contact Information
Kan He
Biotranex LLC
http://www.biotranex.com
+1 (609) 240-8333

Online Web 2.0 Version
You can read the online version of this press release here.